Successful quarter for Diamyd
Elisabeth Lindner, President and CEO of Diamyd Medical, communicates in the CEO
overview in the quarterly report published today, that the last quarter has been
both successful and of vital importance to the development of the company.
Phase III studies have been approved and initiated in Sweden and the US, and
approvals are expected from a number of European countries in August and
September. Inclusion of patients is ongoing in Sweden and ethics approvals for
participating US sites have started to come in.
A successful direct placement was accomplished and warrants have been listed for
trading.
To date, all pursued and planned clinical trials with Diamyd® concern patients
diagnosed with type 1 diabetes or LADA. The Chairman of TrialNet, Professor Jay
Skyler, communicated during the ADA conference in San Fransisco on 9th of June,
that in addition to the planned intervention study with 126 patients, a
prevention study with Diamyd® in healthy individuals at risk to develop type 1
diabetes is planned.
- Diamyd Medical has experienced a fantastic quarter, says President and CEO
Elisabeth Lindner. We have, as a fairly small research company, in a very short
period of time, succeeded to move our Phase III studies into a phase where we
are actively including patients. Furthermore, there is interest from TrialNet to
study whether Diamyd® can prevent type 1 diabetes. Should Diamyd® not only
improve the situation for children, that already have diabetes, but also prevent
the disease, this would be a dramatic break-through. Finally, our financial
position is strengthened after a fully subscribed direct issue of new shares. It
is with great pleasure that I am publishing this quarterly report, concludes
President and CEO Elisabeth Lindner.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),
elisabeth.lindner@diamyd.com
Phone: +46-8-661 0026
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB,
sonja.catani@diamyd.com
Phone: +46-8-661 00 26
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68
E-post: info@diamyd.com. VATno: SE556530-142001.
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials have been initiated in both the US and
Europe. Furthermore the company has initiated clinical studies within chronic
pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has
also out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
